Sign in
FSTX Stock Price, Chart, Stats & News
F-star Therapeutics, Inc.
Save
F-star Therapeutics, Inc. (FSTX) does not currently pay a dividend.
156.51M
Market cap
–
Current P/E
–
Forward P/E
FSTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -145.10% |
Pretax margin | -149.55% |
Net margin | -147.79% |
Effective tax rate | 1.18% |
ROA | -25.43% |
ROE | -44.74% |
D/E | 0.14x |
Interest coverage ratio | -36.39x |
FSTX valuation
P/E | – |
P/S | 7.39x |
P/B | 1.22x |
P/CF | -4.35x |
P/FCF | -5.60x |
P/OCF | -4.35x |
PEG | -0.04x |
EV multiple | -7.54x |
About
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study.
Similar securities
Based on sector and market capitalization
Report issue